Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adeno...
Q1 2026
May 15, 2026
FY 2025
Mar 30, 2026
Q4 2025
Q3 2025
Nov 12, 2025
Q2 2025
Aug 13, 2025